Skip to Content
Merck
CN
  • [Long-term remission of Langerhans cell sarcoma by AIM regimen combined with involved-field irradiation].

[Long-term remission of Langerhans cell sarcoma by AIM regimen combined with involved-field irradiation].

[Rinsho ketsueki] The Japanese journal of clinical hematology (2012-12-22)
Ikuo Shimizu, Wataru Takeda, Takehiko Kirihara, Keijiro Sato, Yuko Fujikawa, Toshimitsu Ueki, Masahiko Sumi, Mayumi Ueno, Naoaki Ichikawa, Hikaru Kobayashi, Masahide Watanabe, Takeshi Uehara, Shigeo Nakamura
ABSTRACT

A 67-year-old woman presented with a right inguinal mass in May 2006. CT scan showed lymph node involvement from the right inguinal to the common iliac and (18)F-FDG-PET revealed uptake in those areas. Biopsy results indicated Langerhans cell sarcoma (LCS). Interestingly, tumor cells expressed a high MIB1 index of 30%. We administered doxorubicin, ifosfamide, and mesna (AIM) chemotherapy, which were reported to effectively treat soft tissue sarcoma. After 5 courses of AIM therapy and involved-field radiation for residual diseases and a relapsed lesion on her right cervical node, she has remained in complete remission for more than 4 years. LCS is an intractable malignant disease and the optimal therapeutic strategy remains unclear. The AIM regimen combined with radiation therapy may be an effective treatment option for this disease.

MATERIALS
Product Number
Brand
Product Description

Supelco
Sodium 2-mercaptoethanesulfonate, analytical standard, ≥98.0% (titration)
Sigma-Aldrich
Sodium 2-mercaptoethanesulfonate, BioXtra, ≥98.0% (RT)
Sigma-Aldrich
2-Mercaptoethanesulfonic acid solution, ampule, 3.0 M±0.1 M in H2O (T)
Sigma-Aldrich
Ifosfamide, ≥98%